ARGENTA DUNDEE LIMITEDActive

Company number SC553262Private limited companyIncorporated 2016

Key figures

£9,547,724+16.1%
Net assets 2021
+16.1%
Average annual growth 2020–2021
02.5 m5 m7.5 m10 m20202021

Ratios

2021
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
010 m20 m20202021
Filed accounts2020–2021
20202021
Turnover16,568,17012,977,593
Profit for the year2,153,3141,327,399
Cash at bank and in hand2,207,274862,044
Total assets15,417,68119,648,033
Total liabilities——
Net assets / total equity8,220,3259,547,724
Average number of employees105112
Average pay (per year)56,84851,544

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2021

The principal activity of the company is the contract manufacture and supply of products for the animal healthcare industry.

As described in the company's latest filed accounts.

Summary: ARGENTA DUNDEE LIMITED

Company

ARGENTA DUNDEE LIMITED is a private limited company registered with Companies House under company number SC553262. It was incorporated on 22 Dec 2016. Its status is active. The registered office is in Glasgow (G2). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100), manufacture of pharmaceutical preparations (21200).

Accounts

The latest accounts in the database are for 2021 (period ending 31 Dec 2021); the company files audit-exempt subsidiary. Turnover was £12,977,593. Profit for the year was £1,327,399. Net assets were £9,547,724, up 16.1% on the previous year. Cash at bank and in hand was £862,044. The company had an average of 112 employees. Figures are available for 2 financial years (2020–2021).

Control and charges

One person with significant control is registered. 3 of 6 registered charges are outstanding.

Filing deadlines

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 11 Feb 2027.